Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

7 trials tracked for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 7 in phase 3 or 4 and 2 with published results. The most-cited published study has 75 citations.

7Trials tracked
7Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 7
  1. Phase 3 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed · 75 cited
  2. Phase 3 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Completed · 43 cited
  3. Phase 3 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed
  4. Phase 3 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed
  5. Phase 3 A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed
  6. Phase 3 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Completed
Show 1 more trials
  1. Phase 3 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: what the trials found

Clinical evidence for Chronic Inflammatory Demyelinating Polyradiculoneuropathy includes several pharmacological interventions with varying outcomes on disability scales and physical metrics. NewGam demonstrated improvements in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score, Grip Strength Score, and Inflammatory Rasch-built Overall Disability Scale (I-RODS Score) 2. Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified showed a significant difference in responder rates between treatment groups (54.2 vs 20.7; p<0.001) and significant improvements in Grip Strength (p<0.001), though it did not significantly change the amplitude of the most severely affected motor nerve (p=0.542) 7.

HYQVIA demonstrated a statistically significant reduction in relapse rates during Epoch 1 (31.4 vs 9.7; p=0.0045) and a significant improvement in the Rasch-built Overall Disability Scale (R-ODS) from baseline (-6.1 vs -0.9; p=0.030). However, its impact on the percentage of participants experiencing worsening functional disability did not reach statistical significance (p=0.0896) 4. Additionally, HYQVIA was associated with a 7.1% rate of treatment-emergent adverse events potentially resulting from immune-mediated responses 3.

Other interventions showed varying results: I10E demonstrated a responder rate of 32 (p<0.0001) 5, while Fingolimod showed no significant difference in time to first confirmed worsening on the adjusted INCAT scale (721.0 vs 540.0; p=0.9838) 1. IgPro20 showed no change from baseline in CIDP total adjusted INCAT scores or Medical Research Council (MRC) scores, with a 75.6% incidence of adverse events 6.

For the clinician treating this condition

  • NewGam and Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified are associated with measurable improvements in grip strength and disability scores [2, 7].
  • HYQVIA significantly reduces relapse rates and improves R-ODS scores compared to baseline, though its effect on worsening functional disability is not statistically confirmed 4.
  • Fingolimod did not show a statistically significant impact on the time to first confirmed worsening on the adjusted INCAT scale 1.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PLEX and corticosteroids show highest clinical response rates in chronic inflammatory demyelinating polyradiculoneuropathy
Pediatrics Meta-analysis
PLEX and corticosteroids show highest clinical response rates in chronic inflammatory demyelinating polyradiculoneuropathy New FcRn Inhibitors Show Promise for Chronic Inflammatory Neuropathy
This systematic review and network meta-analysis of 2,184 patients evaluated various treatments for chronic inflammatory demyelinating polyr…
Newer treatments like efgartigimod alfa may offer significant clinical responses and improved grip strength for patients with chronic inflam…
Frontiers Sep 15, 2026
Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
Neurology Sys. Review
Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders Diabetes May Influence Risk and Progress of Neurological Disorders
This narrative review synthesizes evidence regarding the role of diabetes mellitus (DM) as a disease modifier across various neurological co…
New research suggests that diabetes can change how certain neurological conditions progress, potentially opening doors for new treatment opt…
Frontiers Jun 26, 2026